search
CAR T therapy
Trends
- 1UConn Health Launches CAR-T Cell Therapy Program▼UConn Health Launches Cutting-Edge CAR-T Cell Therapy Program
UConn Health has announced the launch of a new CAR-T cell therapy program, bringing an advanced form of immunotherapy to its medical center in Connecticut. CAR-T treatment reengineers a patient's own immune cells to fight certain cancers, and the program is being promoted as a cutting-edge addition to the institution's clinical services.
- 2Vyriad Launches First-in-Human Trial of CAR T Therapy VV169▼Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169
Biotech company Vyriad has begun the first-in-human clinical trial of VV169, an in vivo CAR T therapy that engineers immune cells inside the patient's body rather than in a lab. The early-stage trial marks a first step in testing the safety of the experimental cancer treatment in people, an approach watched closely as it could simplify a cell therapy process that is currently complex and costly.
- 3Anitocabtagene autoleucel shows sustained response in multiple myeloma▼Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma
Anitocabtagene autoleucel, a cell therapy, is associated with sustained clinical responses in patients with heavily pretreated multiple myeloma, according to a report in medical news. The finding is notable for a disease where patients who have exhausted standard lines of treatment typically face poor outcomes. Clinicians are watching whether such CAR-T approaches can extend durable remissions.